Brief: Tela Bio Announces Publication Of 24-Month Bravo Study Results Demonstrating Benefits Of Ovitex® Reinforced Tissue Matrix In Hernia Repair
26/10/2022 12:08
Oct 26 (Reuters) - TELA Bio Inc TELA.O :
* TELA BIO ANNOUNCES PUBLICATION OF 24-MONTH BRAVO STUDY
RESULTS
DEMONSTRATING BENEFITS OF OVITEX® REINFORCED TISSUE MATRIX IN
HERNIA REPAIR
Source text for Eikon: ID:nGNX3gpb5T
Further company coverage: TELA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TELA Bio
See all newsTELA Bio Q1 revenue growth beats estimates, loss widens
Brief: TELA Bio Q1 Revenue USD 19.059 Million Vs. IBES Estimate USD 18.6 Million
Brief: Tela Bio Announces Inducement Grants Under Nasdaq Listing Rule
Medical device maker Becton Dickinson sued over alleged hernia mesh monopoly
Brief: TELA Bio Announces Pricing Of $13.0 Million Underwritten Registered Direct Offering Of Common Stock And Pre-Funded Warrants